origin mammaglobin and Gross Cystic Disease Fluid Protein (GCDFP-15), they compared a subset of pure NEBC (n = 9) with a cohort of non-mammary neuroendocrine tumors. In their hands, mammaglobin was positive in 4 out of 9 tumors while GCDFP-15 was expressed in 6 out of 9 cases. In three patients, both markers were negative. Remarkably, they did not find any expression of mammaglobin or GCFFP-15 in immunohistochemical evaluation of chromogranin A/synaptophysin-positive non-mammary neuroendocrine tumors [7] .
We have recently determined the incidence, clinicopathological features and immunohistochemical profiling of primary pure NEBC in a large series of infiltrating breast tumors collected from 1989 to 2010 in our institution (Dr. Josep Trueta University Hospital, Girona, Catalonia). From the entire series of more than 1500 carcinomas, only 8 cases fully satisfied the primary pure NEBC criteria by the WHO (i.e., the presence of [50% tumor immunoreactivity for one of neuroendocrine markers including chromogranin, synaptophysin, and CD56), which constitutes an incidence of solid NEBC as low as 0.5% [data updated from ref . 8] . To definitely confirm the primary nature of these endocrine tumors, we recently tested the hypothesis that mammaglobin stating can help, in combination with GCDFP-15 (a sensitive and specific marker of breast carcinoma), to establish the correct diagnosis of breast carcinomas [9] . Table 1 summarizes the immunohistochemical profile for the expression of estrogen receptor (ER), progesterone receptor (PR), HER2, mammaglobin, and GCDFP-15 in tumor specimens from NEBC patients. Our findings largely recapitulate those presented by RichterEhrenstein et al. [7] . All NEBC expressed high levels of estrogen and progesterone receptors. Mammaglobin was positive in 4 out of 9 samples. In contrast, GCDFP-15 was expressed in 7 out of 9 specimens (Fig. 1) . We did not observe discordant expression of mammaglobin and GCDFP-15 markers between primary and metastatic tissues in a patient that debuted with metastasis in the soft tissue of the check before diagnosis of primary NEBC. It was intriguing that HER2 2? staining (but absence of gene amplification) was found in the sole NEBC that was negative for both markers. Richter-Ehrenstein et al. [7] similarly reported that HER2 overexpression was found in only one NEBC, which was negative for both the markers. Although very small number of cases obviously limits the relevance of the correlation between HER2 positivity and mammaglobin/GCDFP-15 double-negative NEBC patients, additional studies with longer follow-up and more cases need to be further pursued to establish whether this ''combimarker'' (i.e., detecting HER2 overexpression in the absence of mammaglobin/GCDFP-15 markers) may delineate a distinctive subgroup of luminal B-like (i.e., ERpositive or PR-positive and HER2-positive [10] ) among the well-established ER/PR-positive HER2-negative status of NEBC. Although GCDFP-15 has classically been considered a secretary marker of apocrine differentiation in breast cancer [11, 12] , the fact that the GCDFP-15 positivity is transient (i.e., breast cancer cases which have apocrine features but lack GCDFP-15 expression suggest advanced apocrine carcinomas [13] ) together with the pre-clinical finding that the prolactin-inducible protein PIP/GCDFP-15 gene was the mostly up-regulated mRNA in luminal B (ER-/HER2-positive) BT-474 breast cancer cells treated with the insulin-like growth factor-I receptor (IGF-IR) antagonist NVP-AEW541 and the anti-HER2 monoclonal antibody trastuzumab [13] , reinforce the suggestion that yet to be established regulatory relationship between GCDFP-15, HER2, and apocrine differentiation would take place in subsets of NEBC [14] [15] [16] .
In summary, our findings strongly support RichterEhrenstein's conclusion that mammaglobin and GCDFP-15 as markers of epithelial breast origin may efficiently work as a new reliable diagnostic tool to distinguish endocrine tumors of the breast from a metastatic non-mammary neuroendocrine disease. Given that the diagnosis of NEBC cases has been made mostly following surgical intervention including mastectomy and that most studies have confirmed that NEBC show a less aggressive clinical behavior when compared with unselected breast cancers, these findings strongly suggest that when suspecting neuroendocrine differentiation, preoperative pathological diagnosis by core biopsies can be employed to immunohistochemically establish the primary nature of mammary NEBC to guide in their conservative medical and surgical management. Further research effort using large clinically annotated series of breast tumors is warranted to definitely establish whether NEBC defined by two-(chromogranin A and synaptophysin) or five (chromogranin A, synaptophysin, HER2, mammaglobin, and GCDFP-15)-biomarker surrogate panels might explain a recent suggestion of invasive NEBC as a distinctive subtype of biologically aggressive breast cancer [17] . 
